N-[2-(diethylamino)ethyl]-3-[2-(1-naphthyl)ethoxy]-N-(2-oxoethyl)propanamide | 1046448-42-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: N-[2-(diethylamino)ethyl]-3-[2-(1-naphthyl)ethoxy]-N-(2-oxoethyl)propanamide
• 英文别名: N-[2-(diethylamino)ethyl]-3-(2-naphthalen-1-ylethoxy)-N-(2-oxoethyl)propanamide
• CAS: 1046448-42-3
• 化学式: C₂₃H₃₂N₂O₃
• 分子量: 384.519
• InChiKey: OJRGQMOUBIAFJF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  28
• 可旋转键数：
  13
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  49.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  7-(2-aminoethyl)-4-hydroxy-1,3-benzothiazol-2(3H)-one hydrochloride 、 N-[2-(diethylamino)ethyl]-3-[2-(1-naphthyl)ethoxy]-N-(2-oxoethyl)propanamide 在 sodium cyanoborohydride 、 氨 作用下， 以 甲醇 、 水 、 溶剂黄146 为溶剂， 反应 0.5h， 生成 N-[2-(diethylamino)ethyl]-N-(2-{[2-(4-hydroxy-2-oxo-2,3-dihydrodihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-3-[2-(1-naphthyl)ethoxy]propanamide
  参考文献：
  名称：

  WO2008/96111

  摘要：

  公开号：
• 作为产物：
  描述：

  1-萘甲醇 在 草酰氯 、 苄基三甲基氢氧化铵 、 N,N-二甲基甲酰胺 、 三氟乙酸 作用下， 以 甲醇 、 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 3.75h， 生成 N-[2-(diethylamino)ethyl]-3-[2-(1-naphthyl)ethoxy]-N-(2-oxoethyl)propanamide
  参考文献：
  名称：

  Discovery of AZD3199, An Inhaled Ultralong Acting β₂ Receptor Agonist with Rapid Onset of Action

  摘要：

  A series of dibasic des-hydroxy beta(2) receptor agonists has been prepared and evaluated for potential as inhaled ultralong acting bronchodilators. Determination of activities at the human beta-adrenoreceptors demonstrated a series of highly potent and selective beta(2) receptor agonists that were progressed to further study in a guinea pig histamine-induced bronchoconstriction model. Following further assessment by onset studies in guinea pig tracheal rings and human bronchial rings contracted with methacholine (guinea pigs) or carbachol (humans), duration of action studies in guinea pigs after intratracheal (i.t.) administration and further selectivity and safety profiling AZD3199 was shown to have an excellent over all profile and was progressed into clinical evaluation as a new ultralong acting inhaled beta(2) receptor agonist with rapid onset of action.

  DOI：

  10.1021/ml4005232

文献信息

• New Combination 665
  申请人：Cadogan Elaine Bridget

  公开号：US20080242649A1

  公开（公告）日：2008-10-02

  The invention provides a pharmaceutical product comprising a first active ingredient which is N—[2-(Diethylamino)ethyl]-N-(2-[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-3-[2-(1-naphthyl)ethoxy]propanamide or a salt thereof, and a second active ingredient selected from: a non-steroidal Glucocorticoid Receptor (GR Receptor) Agonist; an antioxidant; a CCR1 antagonist; a chemokine antagonist (not CCR1); a corticosteroid; a CRTh2 antagonist; a DP1 antagonist; an Histone Deacetylase Inducer; an IKK2 inhibitor; a COX inhibitor; a lipoxygenase inhibitor; a leukotriene receptor antagonist; an MPO inhibitor; a muscarinic antagonist which is Aclidinium bromide, Glycopyrrolate, Oxitropium bromide, Pirenzepine, telenzepine, Tiotropium bromide, 3(R)—(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide, 3(R)—1-phenethyl-3-(9H-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2]octane bromide or (3R)—3-[(2S)—2-cyclopentyl-2-hydroxy-2-thien-2-ylacetoxy]-1-(2-phenoxyethyl)-1-azoniabicyclo[2.2.2]actane bromide; a p38 inhibitor; a PDE inhibitor; a PPARγ agonist; a protease inhibitor; a Statin; a thromboxane antagonist; a vasodilator; or, an ENAC blocker (Epithelial Sodium-channel blocker); and its use in the treatment of respiratory disease.

  本发明提供了一种药物产品，其中包括第一活性成分，该成分为N-[2-(二乙氨基)乙基]-N-(2-[2-(4-羟基-2-氧代-2,3-二氢-1,3-苯并噻唑-7-基)乙基]氨基}乙基)-3-[2-(1-萘基)乙氧基]丙酰胺或其盐，并且包括第二活性成分，所述第二活性成分选自：非类固醇糖皮质激素受体（GR受体）激动剂；抗氧化剂；CCR1拮抗剂；趋化因子拮抗剂（非CCR1）；皮质类固醇；CRTh2拮抗剂；DP1拮抗剂；组蛋白去乙酰化酶诱导剂；IKK2抑制剂；COX抑制剂；脂氧合酶抑制剂；白三烯受体拮抗剂；MPO抑制剂；Aclidinium溴化物、Glycopyrrolate、Oxitropium溴化物、Pirenzepine、telenzepine、Tiotropium溴化物、3(R)-（2-羟基-2,2-二硫基-2-乙酰氧基）-1-(3-苯氧基丙基)-1-氮杂双环[2.2.2]辛烷溴化物、3(R)-1-苯乙基-3-(9H-黄酮-9-羧酰氧基)-1-氮杂双环[2.2.2]辛烷溴化物或（3R）-3-[(2S)-2-环戊基-2-羟基-2-噻唑基乙氧基]-1-(2-苯氧基乙基)-1-氮杂双环[2.2.2]辛烷溴化物；p38抑制剂；PDE抑制剂；PPARγ激动剂；蛋白酶抑制剂；他汀类药物；血栓素拮抗剂；血管扩张剂；或ENAC阻滞剂（上皮钠通道阻滞剂），以及其在呼吸系统疾病治疗中的应用。
• Salts 668
  申请人：Whittock Robert

  公开号：US20080249145A1

  公开（公告）日：2008-10-09

  A pharmaceutically acceptable salt of N-[2-(Diethylamino)ethyl]-N-(2-[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-3-[2-(1-naphthyl)ethoxy]propanamide provided it is not the dihydrobromide or dihydrochloride salt; and the use of such a compound as a medicament (for example in the treatment of respiratory diseases (such as asthma or COPD).

  一种药用可接受的盐，其化学式为N-[2-(二乙氨基)乙基]-N-(2-[2-(4-羟基-2-氧代-2,3-二氢-1,3-苯并噻唑-7-基)乙基]氨基}乙基)-3-[2-(1-萘基)乙氧基]丙酰胺，前提是它不是二氢溴化物盐或二氢氯化物盐；以及将该化合物用作药物（例如用于治疗呼吸系统疾病（如哮喘或COPD）。
• Combinations of Beta-2-Adrenoceptor Agonistic Benzothiazolone
  申请人：Cadogan Elaine Bridget

  公开号：US20100029732A1

  公开（公告）日：2010-02-04

  The invention provides a pharmaceutical product comprising a first active ingredient which is N-[2-(Diethylamino)ethyl]-N-(2-[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-3-[2-(1-naphthyl)ethoxy]propan amide or a salt thereof, and a second active ingredient selected from: a non-steroidal Glucocorticoid Receptor (GR Receptor)=Agonist; an antioxidant; a CCR1 antagonist; a chemokine antagonist (not CCR1); a corticosteroid; a CRTh2 antagonist; a DP1 antagonist; an Histone Deacetylase Inducer; an IKK2 inhibitor; a COX inhibitor; a lipoxygenase inhibitor; a leukotriene receptor antagonist; an MPO inhibitor; a muscarinic antagonist which is Aclidinium bromide, Glycopyrrolate, Oxitropium bromide, Pirenzepine, telenzepine, Tiotropium bromide, 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azo-niabicyclo[2.2.2]octane bromide, 3(R)- 1 -phenethyl-3-(9H-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2]octane bromide or (3R)-3-[(2S)-2-cyclopentyl-2-hydroxy-2-thien-2-ylacetoxy]-1-(2-phenoxyethyl)-1-azoniabicyclo[2.2.2]actane bromide; a p38 inhibitor; a PDE inhibitor; a PPARy agonist; a protease inhibitor; a Statin; a thromboxane antagonist; a vasodilator; or, an ENAC blocker (Epithelial Sodium-channel blocker); and its use in the treatment of respiratory disease.

  该发明提供了一种药物产品，包括第一活性成分为N-[2-(二乙氨基)乙基]-N-(2-[2-(4-羟基-2-氧代-2,3-二氢-1,3-苯并噻唑-7-基)乙基]氨基}乙基)-3-[2-(1-萘基)乙氧基]丙酰胺或其盐，和第二活性成分从以下中选择：非甾体型糖皮质激素受体（GR受体）=激动剂；抗氧化剂；CCR1拮抗剂；趋化因子拮抗剂（非CCR1）；类固醇；CRTh2拮抗剂；DP1拮抗剂；组蛋白去乙酰化酶诱导剂；IKK2抑制剂；COX抑制剂；脂氧合酶抑制剂；白三烯受体拮抗剂；MPO抑制剂；Aclidinium溴化物，Glycopyrrolate，Oxitropium溴化物，Pirenzepine，telenzepine，Tiotropium溴化物，3(R)-(2-羟基-2,2-二噻吩-2-乙氧基)-1-(3-苯氧基丙基)-1-氮杂双环[2.2.2]辛烷溴化物，3(R)-1-苯乙基-3-(9H-黄酮-9-羰基氧基)-1-氮杂双环[2.2.2]辛烷溴化物或(3R)-3-[(2S)-2-环戊基-2-羟基-2-噻吩-2-乙氧基]-1-(2-苯氧基乙基)-1-氮杂双环[2.2.2]辛烷溴化物；p38抑制剂；PDE抑制剂；PPARy激动剂；蛋白酶抑制剂；他汀类药物；血栓素受体拮抗剂；血管扩张剂；或ENAC阻滞剂（上皮钠通道阻滞剂），以及其在呼吸道疾病治疗中的应用。
• Novel Benzothiazolone Derivatives
  申请人：Bonnert Roger

  公开号：US20080300275A1

  公开（公告）日：2008-12-04

  The present invention provides compounds of formula (I) wherein e, R 1 , R 2 , R 3 , R 4 , R 5 , R 4 , R 5 , R 6 , R 7 , R 7a , R 7b , A, D, m and n are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明提供了公式（I）化合物，其中e，R1，R2，R3，R4，R5，R4，R5，R6，R7，R7a，R7b，A，D，m和n如说明书中所定义，以及其制备方法，包含它们的制药组合物以及它们在治疗中的用途。
• COMBINATION OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST
  申请人：Harry Finch

  公开号：US20110046191A1

  公开（公告）日：2011-02-24

  The invention provides a pharmaceutical product, kit or composition comprising a first active ingredient which is a selected muscarinic receptor antagonist selected, and a second active ingredient which is a β 2 -adrenoceptor agonist, of use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease and asthma.

  该发明提供了一种药品、试剂盒或组合物，包括第一活性成分，该成分为选择的肌动蛋白受体拮抗剂，以及第二活性成分，该成分为β2-肾上腺素能受体激动剂，用于治疗慢性阻塞性肺疾病和哮喘等呼吸系统疾病。